Market›Health Care›Biotechnology›Biotechnology
ALIGOS THERAPEUTICS Equity

ALGS

$6.40Apr 26, 2021 – Apr 24, 2026
Health CareBiotechnology$49M
MVM
+$0.3M
TD Variance
6.506

Every news event mapped to its market reaction — 98 events, 61 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2022-01-06-62.7%legalSEC EDGARALGS 8-K: 8.01 (SEC Filing)
2024-09-19-36.7%newsSeeking AlphaAligos posts initial mid-stage trial results for MASH candidate
2023-10-23-20.4%newsSeeking AlphaAligos Therapeutics stock plummets on $92M private placement financing
2025-02-12-20.0%newsSeeking AlphaAligos Therapeutics looks to raise $105 million in private placement
2025-02-12-20.0%legalSEC EDGARALGS 8-K: 1.01, 3.02, 7.01 (SEC Filing)
2026-01-07+18.3%newsYahoo FinanceHere's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely - Yahoo Finance
2024-08-06+18.2%earningsSeeking AlphaAligos Therapeutics GAAP EPS of $0.03 beats by $0.19
2024-08-06+18.2%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2026-04-14-16.1%legalGlobeNewswireAligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
2026-04-14-16.1%legalSEC EDGARALGS 8-K: 8.01 and (SEC Filing)
2026-04-17-16.0%M&APharmaceutical TechnologyAligos and Xiamen Amoytop sign deal for HBV therapy
2026-04-17-16.0%newsSahmAligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates - Sahm
2025-03-10-15.3%earningsSeeking AlphaAligos Therapeutics GAAP EPS of -$13.08 misses by $10.58
2025-03-10-15.3%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2023-11-17+14.5%newsSeeking AlphaAligos Therapeutics files to sell 168.73M shares of common stock
2025-05-06-13.2%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2022-08-04+13.0%earningsSeeking AlphaAligos Therapeutics GAAP EPS of -$0.47 beats by $0.18, revenue of $3.69M
2022-08-04+13.0%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2021-04-27-12.9%legalSEC EDGARALGS 8-K: 5.02 (SEC Filing)
2025-11-21+12.7%newsSeeking AlphaAligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript
2026-02-04-12.0%legalSEC EDGARALGS 8-K: 5.02 (SEC Filing)
2026-04-16-11.4%M&AGlobeNewswireAligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
2026-04-16-11.4%M&ASeeking AlphaAligos Therapeutics jumps 22% on Greater China deal for Hepatitis B drug
2026-04-16-11.4%M&AStock TitanMore than 90 million live with HBV in Greater China; Aligos signs deal - Stock Titan
2022-05-04-11.4%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2023-11-22+9.4%legalSEC EDGARALGS 8-K: 5.02 (SEC Filing)
2024-09-05+8.5%legalSEC EDGARALGS 8-K: 8.01 (SEC Filing)
2023-10-25+7.7%legalSEC EDGARALGS 8-K: 1.01, 3.02 (SEC Filing)
2024-12-11+7.2%newsSeeking AlphaAligos Therapeutics: Promising Pipeline With Cash And Dilution Risks
2024-12-11+7.2%newsSeeking AlphaAligos Therapeutics: Promising Pipeline With Cash And Dilution Risks (NASDAQ:ALGS) - Seeking Alpha
2026-04-22-7.2%newsIntellectia AIAI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI
2025-06-26-6.8%legalSEC EDGARALGS 8-K: 5.02, 5.03, 5.07 (SEC Filing)
2023-05-04-6.5%earningsSeeking AlphaAligos Therapeutics GAAP EPS of -$0.53 misses by $0.05, revenue of $2.58M
2023-05-04-6.5%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2021-05-15+6.4%analystBenzingaAligos Therapeutics Analyst Ratings and Price Targets | NASDAQ:ALGS - Benzinga
2024-05-15-6.4%legalSEC EDGARALGS 8-K: 5.02 (SEC Filing)
2021-11-04+6.1%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2026-03-11+6.0%newsStock TitanAligos Therapeutics (ALGS) officer awarded 23,310 stock options at $7.03 strike - Stock Titan
2022-07-25-5.9%newsSeeking AlphaAligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B
2021-06-24+5.9%legalSEC EDGARALGS 8-K: 5.02 (SEC Filing)
2023-05-15+5.8%newsSeeking AlphaAligos Therapeutics and Xiamen Amoytop Biotech join hands for the treatment of liver diseases
2023-03-09-5.7%earningsSeeking AlphaAligos Therapeutics GAAP EPS of -$0.51 misses by $0.02, revenue of $3.54M beats by $1.39M
2023-03-09-5.7%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2023-02-08-5.6%newsSeeking AlphaAligos Therapeutics in portfolio reorganization focused on NASH, COVID assets
2024-05-22-5.1%legalSEC EDGARALGS 8-K: 3.01 and 5.02 (SEC Filing)
2023-10-18+4.9%legalSEC EDGARALGS 8-K: 8.01 (SEC Filing)
2026-01-21+4.9%newsStock TitanHepatitis B study hits key 2026 milestones as Aligos seeks new CMO - Stock Titan
2023-10-30-4.9%newsSeeking AlphaAligos Therapeutics director buys shares worth $6M
2023-11-15+4.7%legalSEC EDGARALGS 8-K: 5.02 (SEC Filing)
2026-02-13-4.7%newsIntellectia AIAI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI
2026-02-23+4.6%newsGlobeNewswireAligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
2024-08-15+4.5%newsSeeking AlphaAligos Therapeutics announces reverse stock split
2024-02-28+4.0%legalSEC EDGARALGS 8-K: 5.02 (SEC Filing)
2026-03-05+3.6%newsGlobeNewswireAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
2026-03-05+3.6%earningsSeeking AlphaAligos Therapeutics GAAP EPS of -$1.91 beats by $0.12
2026-03-05+3.6%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2022-11-02+3.5%earningsSeeking AlphaAligos Therapeutics GAAP EPS of -$0.44 beats by $0.14, revenue of $4.12M beats by $3.37M
2022-11-02+3.5%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2024-05-07-3.5%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2025-03-27-3.3%newsSeeking AlphaAligos Therapeutics files to sell 6.25M shares of common stock for holders
2022-03-30+2.8%legalSEC EDGARALGS 8-K: 8.01 (SEC Filing)
2024-03-31-2.8%newsCNNsymbol__ Stock Quote Price and Forecast - CNN
2023-09-03+2.6%analystZacks Investment ResearchWhat is the current Price Target and Forecast for Aligos Therapeutics (ALGS) - Zacks Investment Research
2023-08-01+2.6%legalSEC EDGARALGS 8-K: 8.01 (SEC Filing)
2025-11-06-2.6%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2022-03-10+2.5%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2024-11-06-2.4%legalSeeking AlphaAligos Therapeutics files $400M mixed securities shelf
2024-11-06-2.4%earningsSeeking AlphaAligos Therapeutics EPS of -$3.07 misses by $1.75
2024-11-06-2.4%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2026-02-26+2.3%newsGlobeNewswireAligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
2024-05-08-2.2%earningsSeeking AlphaAligos Therapeutics reports Q1 results
2024-06-28-2.2%legalSEC EDGARALGS 8-K: 5.02, 5.03, 5.07 (SEC Filing)
2025-08-06+2.1%earningsSeeking AlphaAligos Therapeutics GAAP EPS of -$1.53 beats by $0.83
2025-08-06+2.1%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2024-03-12-2.1%earningsSeeking AlphaAligos Therapeutics GAAP EPS of -$0.22 beats by $0.05, revenue of $2.68M beats by $1.08M
2024-03-12-2.1%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2022-03-22-2.0%legalSEC EDGARALGS 8-K: 8.01 (SEC Filing)
2024-08-08-1.8%legalSEC EDGARALGS 8-K: 5.02 (SEC Filing)
2024-08-08-1.8%newsStock TitanAligos Therapeutics Strengthens Board with Two New Independent Directors - Stock Titan
2021-11-18-1.8%legalSEC EDGARALGS 8-K: 5.02 (SEC Filing)
2023-11-02-1.5%earningsSeeking AlphaAligos Therapeutics GAAP EPS of -$0.41
2023-11-02-1.5%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2024-09-24+1.4%executiveSeeking AlphaAligos Therapeutics names Hardean Achneck as chief medical officer
2025-04-24-1.2%newsStock TitanALGS Stock Price, News & Analysis - Stock Titan
2021-08-05+1.1%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2025-02-03+0.9%legalSEC EDGARALGS 8-K: 5.02 (SEC Filing)
2023-08-03-0.7%earningsSeeking AlphaAligos Therapeutics GAAP EPS of -$0.43 beats by $0.06, revenue of $2.59M
2023-08-03-0.7%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2021-05-10-0.7%legalSEC EDGARALGS 8-K: 2.02 and (SEC Filing)
2026-04-21-0.4%legalSEC EDGARALGS 8-K: 1.01 (SEC Filing)
2024-01-25-0.3%legalSEC EDGARALGS 8-K: 8.01 and (SEC Filing)
2022-09-28+0.2%newsSeeking AlphaAligos Therapeutics files court response and counterclaims to J&J's allegations of theft
2024-10-22-0.1%legalSeeking AlphaAligos gains as FDA clears trial for hepatitis B drug
2025-02-08-0.1%newsYahoo FinanceHere's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely - Yahoo Finance
2025-12-21+0.0%newsTrefisCan Aligos Therapeutics Stock Recover If Markets Fall? - Trefis
2026-04-24—newsGlobeNewswireAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-24—newsStock TitanNew Aligos hires get stock options for 10,700 shares under Nasdaq rule - Stock Titan
2026-04-24—newsThe Manila TimesAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
tickerdossier.comtickerdossier.substack.com